Novel ligustilide derivatives target quorum sensing system LasR/LasB and relieve inflammatory response against Pseudomonas aeruginosa infection
Copyright © 2023 Elsevier Masson SAS. All rights reserved..
The increasing antibiotic resistance driven by Pseudomonas aeruginosa typically leads to uncontrolled and persistent inflammatory damage, which is primarily attributed to the virulence and biofilms produced by the bacteria. Herein, we present a novel anti-infective drug strategy designed to inhibit the bacterial quorum sensing system, thereby attenuating P. aeruginosa virulence, and modulating inflammation from drug-resistant bacterial infections. We discovered new quorum sensing LasR/LasB inhibitors derived from the structural modification of a ligustilide derivative library. Of these compounds, 5f demonstrated significant inhibitory activity against LasB (LasB-gfp, IC50 = 8.7 μM) and a moderate inhibitory effect on P. aeruginosa biofilms (IC50 = 7.4 μM). Through live image analysis in a fluorescent protein-labeled zebrafish larva model, we observed that compound 5f significantly inhibited the migration of macrophages. Moreover, compound 5f effectively attenuated quorum sensing-mediated virulence factors and biofilm formation by P. aeruginosa. It also alleviated the inflammatory response by P. aeruginosa-infected macrophages through the downregulation of mitogen-activated protein kinase and NF-κB signal-transduction pathways. Notably, in vivo experiments, this compound demonstrated marked therapeutic effects in acute lung injury models induced by lipopolysaccharides from P. aeruginosa. These results indicate that compound 5f has the potential to be a novel anti-infective candidate against drug-resistant infections caused by P. aeruginosa.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:263 |
|---|---|
| Enthalten in: |
European journal of medicinal chemistry - 263(2023) vom: 05. Jan., Seite 115972 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Jun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4431-01-0 |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 04.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejmech.2023.115972 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36486821X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36486821X | ||
| 003 | DE-627 | ||
| 005 | 20231226100414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2023.115972 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM36486821X | ||
| 035 | |a (NLM)37995562 | ||
| 035 | |a (PII)S0223-5234(23)00939-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel ligustilide derivatives target quorum sensing system LasR/LasB and relieve inflammatory response against Pseudomonas aeruginosa infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a The increasing antibiotic resistance driven by Pseudomonas aeruginosa typically leads to uncontrolled and persistent inflammatory damage, which is primarily attributed to the virulence and biofilms produced by the bacteria. Herein, we present a novel anti-infective drug strategy designed to inhibit the bacterial quorum sensing system, thereby attenuating P. aeruginosa virulence, and modulating inflammation from drug-resistant bacterial infections. We discovered new quorum sensing LasR/LasB inhibitors derived from the structural modification of a ligustilide derivative library. Of these compounds, 5f demonstrated significant inhibitory activity against LasB (LasB-gfp, IC50 = 8.7 μM) and a moderate inhibitory effect on P. aeruginosa biofilms (IC50 = 7.4 μM). Through live image analysis in a fluorescent protein-labeled zebrafish larva model, we observed that compound 5f significantly inhibited the migration of macrophages. Moreover, compound 5f effectively attenuated quorum sensing-mediated virulence factors and biofilm formation by P. aeruginosa. It also alleviated the inflammatory response by P. aeruginosa-infected macrophages through the downregulation of mitogen-activated protein kinase and NF-κB signal-transduction pathways. Notably, in vivo experiments, this compound demonstrated marked therapeutic effects in acute lung injury models induced by lipopolysaccharides from P. aeruginosa. These results indicate that compound 5f has the potential to be a novel anti-infective candidate against drug-resistant infections caused by P. aeruginosa | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biofilm | |
| 650 | 4 | |a Drug-resistant | |
| 650 | 4 | |a Inflammatory | |
| 650 | 4 | |a Pseudomonas aeruginosa | |
| 650 | 4 | |a Virulence | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a ligustilide |2 NLM | |
| 650 | 7 | |a 4431-01-0 |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 700 | 1 | |a Chen, Qiu-Xian |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Wen-Fu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Si-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jia-Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Yi-Qun |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Shao-Gao |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Jia-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yu-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Jia-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Jiao, Shu-Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Hai-Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jian-Fu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Hai-Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yong-Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Ping-Hua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 263(2023) vom: 05. Jan., Seite 115972 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
| 773 | 1 | 8 | |g volume:263 |g year:2023 |g day:05 |g month:01 |g pages:115972 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2023.115972 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 263 |j 2023 |b 05 |c 01 |h 115972 | ||